277 related articles for article (PubMed ID: 31010004)
1. Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase.
Singh K; Sarafianos SG; Sönnerborg A
Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 31010004
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
3. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
[TBL] [Abstract][Full Text] [Related]
4. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
Chounta V; Snedecor SJ; Wu S; Van de Velde N
BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
[TBL] [Abstract][Full Text] [Related]
6. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of cabotegravir for HIV treatment and prevention.
Canetti D; Spagnuolo V
Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
[No Abstract] [Full Text] [Related]
8. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
9. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
Durham SH; Chahine EB
Ann Pharmacother; 2021 Nov; 55(11):1397-1409. PubMed ID: 33593093
[TBL] [Abstract][Full Text] [Related]
10. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W; Zhao S; Wu Y; Duan W; Li S; Li Z; Guo C; Wang W; Zhang T; Wu H; Huang X
JMIR Public Health Surveill; 2023 Jul; 9():e46767. PubMed ID: 37498645
[TBL] [Abstract][Full Text] [Related]
13. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
14. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
[TBL] [Abstract][Full Text] [Related]
15. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
16. Long-Acting Cabotegravir for HIV/AIDS Prophylaxis.
Engelman KD; Engelman AN
Biochemistry; 2021 Jun; 60(22):1731-1740. PubMed ID: 34029457
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
18. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
Bares SH; Scarsi KK
Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.
Howe ZW; Norman S; Lueken AF; Huesgen E; Farmer EK; Jarrell K; Mathis JE; Bonham KW; Hahn J
Pharmacotherapy; 2021 Aug; 41(8):686-699. PubMed ID: 34130357
[TBL] [Abstract][Full Text] [Related]
20. Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort.
Cervo A; Russo A; Di Carlo D; De Vito A; Fabeni L; D'Anna S; Duca L; Colpani A; Fois M; Zauli B; Mancarella G; Carraro A; Bezenchek A; Cozzi-Lepri A; Santoro MM;
J Glob Antimicrob Resist; 2023 Sep; 34():141-144. PubMed ID: 37453495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
